Our Commitment to Safety Communication
Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience
Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
More than 70,000 patients with RMS or PPMS have started ocrelizumab globally.1
The following ocrelizumab global safety updates are available. Click below to learn more:
Updated Safety Analysis
Additional Topics of Interest
Indications vary in different countries. Please contact your local Roche Affiliate for more information on ocrelizumab.
- Roche data on file. October 2018
Select a Country
Switzerland / Lichtenstein
United Arab Emirates